Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

Key facts

Sponsor

University College, London

Principal Investigator

Paola Giunti

University College, London

Intervention

Positive genetic test for pathological expansion in ATN1(other)

Enrollment

225 enrolled

Eligibility

All sexes

Timeline

2022 – 2026

Study locations (3)

• NYU Grossman School of Medicine, New York, New York, United States
• University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
• University College London, London, United Kingdom

Collaborators

University of North Carolina, Chapel Hill · NYU Langone Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dentatorubral pallidoluysian atrophy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07221760
  Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
  n-Lorem Foundation
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07084311
  Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
  n-Lorem Foundation
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06706388
  Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation
  n-Lorem Foundation
• RECRUITINGNCT05489393
  CureDRPLA Global Patient Registry
  CureDRPLA

See all trials for Dentatorubral pallidoluysian atrophy →